🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Clearance

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians treating patients have voiced hope. Having a one-pill regimen like this is described as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.